^
    Apply
    Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors (NCT03385486)
    Phase 1
    Taiga Biotechnologies, Inc.
    Recruiting
    Last update posted :
    05/03/2022
    Initiation :
    06/02/2019
    Primary completion :
    02/01/2023
    Completion :
    12/01/2024
    CD69
    |
    TBX-3400
    Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies (NCT04640246)
    Phase 1/2
    Taiga Biotechnologies, Inc.
    Recruiting
    Last update posted :
    02/02/2022
    Initiation :
    01/25/2021
    Primary completion :
    01/01/2023
    Completion :
    04/01/2023
    CD69
    |
    TBX-3400